Letter to the editor: Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting?

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 307-308

  Kobunai, Takashi ^a   Watanabe, Toshiaki ^a   Yamamoto, Yoko ^a   Fukusato, Toshio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; KRAS GENE; LETTER; MUTATION RATE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TUMOR CELL; TUMOR GENE; COLON TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; METHODOLOGY; MUTATION; NEOPLASM; NOTE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 79953248568     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.6     Document Type: Letter

References (4)

1. Carotenuto P, Roma C, Rachiglio AM et al.: Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11(8), 1169-1179 (2010).
2. Kobunai T, Watanabe T, Yamamoto Y et al.: The frequency of KRAS mutation detection in human colon carcinoma is infuenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem. Biophys. Res. Commun. 395(1), 158-162 (2010).
3. Bando H, Tsuchihara K, Yoshino T et al.: Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. Jpn J. Clin. Oncol. 41(2), 239-244 (2011)
4. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16(3), 790-799 (2010).